[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2001234596A1 - Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections - Google Patents

Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections

Info

Publication number
AU2001234596A1
AU2001234596A1 AU2001234596A AU3459601A AU2001234596A1 AU 2001234596 A1 AU2001234596 A1 AU 2001234596A1 AU 2001234596 A AU2001234596 A AU 2001234596A AU 3459601 A AU3459601 A AU 3459601A AU 2001234596 A1 AU2001234596 A1 AU 2001234596A1
Authority
AU
Australia
Prior art keywords
castanospermine
substituted
compounds
hepatitis virus
virus infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001234596A
Inventor
Timothy M Block
Raymond A. Dwek
Gary S. Jacob
Robert Jordan
Nicole Zitzmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2001234596A1 publication Critical patent/AU2001234596A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001234596A 2000-01-28 2001-01-29 Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections Abandoned AU2001234596A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17877700P 2000-01-28 2000-01-28
US60178777 2000-01-28
PCT/US2001/002700 WO2001054692A1 (en) 2000-01-28 2001-01-29 Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections

Publications (1)

Publication Number Publication Date
AU2001234596A1 true AU2001234596A1 (en) 2001-08-07

Family

ID=22653908

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001234596A Abandoned AU2001234596A1 (en) 2000-01-28 2001-01-29 Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections

Country Status (2)

Country Link
AU (1) AU2001234596A1 (en)
WO (1) WO2001054692A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
JP2008515816A (en) * 2004-10-06 2008-05-15 ミジェニックス インコーポレイテッド Combination antiviral composition containing castanospermine and method of use thereof
EP1853317A2 (en) * 2005-02-09 2007-11-14 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
CA2659858A1 (en) 2006-08-02 2008-07-24 United Therapeutics Corporation Liposome treatment of viral infections
WO2010109330A2 (en) 2009-03-27 2010-09-30 University Of Oxford Cholesterol level lowering liposomes
WO2014143907A1 (en) 2013-03-15 2014-09-18 60° Pharmaceuticals Llc Novel dosing regimens of celgosivir for the treatment of dengue

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027433D0 (en) * 1990-12-18 1991-02-06 Merrell Dow Pharma Anti-herpes castanospermine esters

Also Published As

Publication number Publication date
WO2001054692A1 (en) 2001-08-02

Similar Documents

Publication Publication Date Title
EP1292603B8 (en) Methods and compositions for treating hepatitis c virus
AU1099000A (en) Novel compounds and compositions for treating hepatitis c infections
AU2002230764A1 (en) Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
EE05442B1 (en) A low dose entecavir pharmaceutical composition for the treatment of hepatitis B virus infection and a method for its preparation
AU2002346686A1 (en) Compositions and method for treating hepatitis virus infection
AU5618501A (en) Dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis
AU2003216523A1 (en) Treatment of pre-core hepatitis b virus mutant infections
AU2001269704A1 (en) Oxazinoquinolones useful for the treatment of viral infections
IL162236A0 (en) Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
AU2001236938A1 (en) Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
AU2001292667A1 (en) Immunogenic composition of hepatitis c and methods of use thereof
AU3858600A (en) Glucamine compounds for treating hepatitis virus infections
AU2281601A (en) Treatment of viral infections using levovirinTM
AU2002324753A1 (en) Composition and method for treating viral infection
AU2001269092A1 (en) Inhibitors of hepatitis b virus infection
AU2001234596A1 (en) Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections
AU2002359327A1 (en) Method of treating viral infections
AU2002365168A1 (en) Method and composition for treating and preventing hiv infection and aids
AU1808501A (en) Tricyclic compounds and method of treating herpes virus
AU2001277055A1 (en) Composition for treatment of and method of monitoring hepatitis c virus using interferon-tau
AU2003254129A1 (en) Method and composition for treating and preventing hepatitis b infection and symptoms thereof
AU2002327531A1 (en) Therapeutic compositions and methods for treating viral infection
AU2001288870A1 (en) Antiviral compounds and method of treating viral infections
HUP0600449A2 (en) Methods of treating liver fibrosis and hepatitis c virus infection